+1.212.901.8009 sclassen@alzdiscovery.org

18th INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY
September 11-12, 2017 • Jersey City, NJ (across from NYC on the Hudson)

Program

All sessions will be held at the Hyatt Regency Jersey City (Manhattan Ballroom, 9th Floor).

Sunday, September 10
5:00–7:00pm On-site Pre-registration
Monday, September 11
8:00am–5:30pmRegistration
8:00–8:30amContinental Breakfast
8:30–8:50Welcome & Opening Presentation: Setting the Stage for New Alzheimer’s Therapeutics
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
8:50–9:20KEYNOTE: Challenges in Developing Microglia--Targeted Therapeutics
Stefan Lohmer, PhD—Axxam SpA
9:20-9:30Discussion and Q&A
Session I: Neuroinflammation
Chair: Nick McKeehan—Alzheimer’s Drug Discovery Foundation

SESSION OVERVIEW: Neuroinflammation has long been recognized as a factor in Alzheimer’s patient brains. Historically, inflammation was thought to be a consequence of the disease process, but new research findings identifying inflammation related genes that increase one’s risk of developing Alzheimer’s have indicated inflammation as a fundamental trigger of disease progression and as a promising therapeutic strategy. The talks in this session will highlight unique neuroinflammation targets and repurposing opportunities relevant to inflammation.
9:30–9:35Session Overview: Nick McKeehan—Alzheimer’s Drug Discovery Foundation
9:35–9:55Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
Milton Greenberg, PhD—Vivreon Biosciences, LLC
9:55–10:05Q&A
10:05–10:25 Fingolimod Therapy in Models of Alzheimer's Disease
Alpaslan Dedeoglu, MD, PhD—Boston VA Medical Center and Boston University
10:25–10:35Q&A
10:35–11:00EXHIBITOR SESSION BREAK
11:00–11:20A Platform for Novel CNS Protein Kinase Inhibitor Discovery: IND-enabling Studies of an Isoform Selective Stress Kinase Inhibitor Candidate
D. Martin Watterson, PhD—Northwestern University
11:20–11:30Q&A
11:30–11:50Nilvad Add-on Study: The Effects of Nilvadipine on Blood Pressure, Cerebral Autoregulation, -Blood Flow and -Damage in Alzheimer's Disease
Jurgen Claassen, MD, PhD—Radboud University Medical Center
11:50am–12:00pmQ&A
12:00–12:20 Phase 1 Clinical Trial Results to Evaluate Safety and Anti-Inflammatory Actions of GC021109 in Patients with Alzheimer's Disease
Philip Haydon, PhD—GliaCure, Inc.
12:20–12:30Q&A
12:30–1:35
LUNCH AND POSTER SESSION
All poster presenters should stand by their poster from 1:00-1:35PM
Session II: Neuroprotection and Neural Regeneration
Chair: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation

SESSION OVERVIEW: Alzheimer’s disease and related dementias are characterized by early loss of synapses and subsequent neurodegeneration. As such, a growing number of programs are developing drugs to enhance neuronal survival and regeneration and inhibit neuronal cell death mechanisms that are activated by injury or stress. This session will feature therapeutic approaches that target neurotrophic factors or hormones that promote neuronal survival, strategies to convert neural stem cells into mature neurons, and approaches to prevent neuronal death.
1:35–1:40Session Overview: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
1:40–2:00Testing of Selective DYRK1A Inhibitors as a Novel Treatment for Alzheimer’s Disease
Travis Dunckley, PhD—Arizona State University
ADDF/Harrington Scholar
2:00–2:10Q&A
2:10–2:30Fragment-Based Inhibitor Design of Human SCPs for Neuron Regeneration
Yan Jessie Zhang, PhD—University of Texas, Austin
2:30–2:40Q&A
2:40–3:00Selective Cyclophilin Inhibitors for Neurodegeneration
Michael Peel, PhD—Cypralis Ltd.
3:00–3:10Q&A
3:10–3:40EXHIBITOR SESSION BREAK
3:40–4:00Therapeutic Potential of Dual Leucine Zipper Kinase Inhibitors in Alzheimer's Disease
William Ray, PhD—MD Anderson Cancer Center
4:00–4:10Q&A
4:10–4:30 Novel Regenerative Disease-modifying Therapies for Alzheimer's Disease
Leen Kawas, PhD—M3 Biotechnology, Inc.
4:30–4:40Q&A
4:40–5:00Results from a Pilot Clinical Trial of Allopregnanolone: A Regenerative Therapy for Alzheimer's Disease
Roberta Diaz Brinton, PhD—University of Arizona Health Sciences
5:00–5:10Q&A
5:10–5:20Closing Remarks and Announcement of Young Investigator Scholarships
Andrew Koemeter-Cox, PhD—Alzheimer’s Drug Discovery Foundation
5:20–7:00NETWORKING RECEPTION
Tuesday, September 12
8:00–8:30amContinental Breakfast
8:30–8:35Day 2 Opening Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
8:35–9:05 KEYNOTE: Applying Radiochemical Approaches to Investigating Novel Targets for Neurodegenerative Disease
Neil Vasdev, PhD—Massachusetts General Hospital and Harvard Medical School
9:05-9:15Discussion and Q&A
Session III: Epigenetics and Cognitive Enhancing
Chair: Yuko Hara, PhD—Alzheimer’s Drug Discovery Foundation

SESSION OVERVIEW: Epigenetic mechanisms may play a role in the onset and progression of Alzheimer’s disease and represent an emerging area for drug development. Currently available FDA-approved drugs for Alzheimer’s disease target the acetylcholinesterase or the NMDA receptor to improve cognitive function. However, many other cognitive-enhancing strategies are under investigation, including those that are approved for other indications. The talks in this session will highlight advances in epigenetic therapeutics, comparative effectiveness research, and drug repurposing in treating or preventing cognitive symptoms associated with Alzheimer’s disease, mild cognitive impairment, and aging.
9:15–9:20 Session Overview: Yuko Hara, PhD—Alzheimer’s Drug Discovery Foundation
9:20–9:40Measuring Synaptic Vesicle Glycoprotein 2A (SV2A) Levels as a Translatable Marker of Pro-synaptic Effects of HDAC Class I Selective Inhibitors
Maria Quinton, PhD—Rodin Therapeutics
9:40–9:50Q&A
9:50–10:10Anti-Hypertension Drug Class: Which is the ‘Best’ at Reducing the Risk for AD?
Lenore Launer, PhD—National Institutes of Health, National Institute on Aging
10:10–10:20Q&A
10:20–10:50EXHIBITOR SESSION BREAK
10:50–11:10Glutamatergic Dysfunction in Cognitive Aging: Repurposing Riluzole for Mild Alzheimer's Disease
Ana Pereira, MD—Icahn School of Medicine at Mount Sinai and The Rockefeller University
11:10–11:20Q&A
11:20–11:40Clinical Development of a Dual LSD1/MAO-B Inhibitor ORY-2001
Tamara Maes, PhD—Oryzon Genomics S.A.
11:40–11:50Q&A
11:50am–12:10pmA Phase IIa, Double-blind, Placebo-controlled, Biomarker Study of Atomoxetine in Subjects with Mild Cognitive Impairment
Allan Levey, MD, PhD—Emory University
12:10–12:20Q&A
12:20–12:50EMERGING CONCEPTS: DATA BLITZ
Chair: Yuko Hara, PhD—Alzheimer’s Drug Discovery Foundation
Young Investigator #1: Mohammad Parvez Alam, PhD—University of California Los Angeles
Young Investigator #2: Hazem Abdelkarim, PhD—University of Illinois at Chicago
Young Investigator #3: Ramon Velazquez, PhD—Arizona State University
12:50–1:45LUNCH AND POSTER SESSION
All poster presenters should stand by their poster from 1:10-1:45PM
Session IV: Misfolded Proteins and Proteostasis
Chair: Andrew Koemeter-Cox—Alzheimer’s Drug Discovery Foundation

SESSION OVERVIEW: A shared feature of many chronic neurodegenerative diseases is the abnormal accumulation and/or aggregation of misfolded proteins, which often have deleterious neurotoxic and inflammatory consequences. Due to this common mechanism, many research programs in the neurodegenerative disease space are exploring strategies to ameliorate the effects of toxic protein species. Talks in this session will cover drug discovery programs pursuing innovative routes towards solving the problem of misfolded proteins and protein accumulation, along with biomarker programs under development.
1:45–1:50Session Overview: Andrew Koemeter-Cox—Alzheimer’s Drug Discovery Foundation
1:50 –2:10Small Molecule PDI Modulators Suppress Neurodegeneration
Brent Stockwell, PhD—Columbia University
2:10–2:20Q&A
2:20–2:40Potent Small Molecule Inducers of Autophagy as Potential Agents to Lower Tau Levels and to Treat Alzheimer's Disease
Steven Finkbeiner, MD, PhD—Gladstone Institutes and University of California, San Francisco
2:40–2:50Q&A
2:50–3:10Mitochondrial TDP-43 as a Novel Therapeutic Target for FTD
Xinglong Wang, PhD—Case Western Reserve University School of Medicine
Funded through ADDF/Association for Frontotemporal Degeneration Partnership Program
3:10–3:20Q&A
3:20-3:40Tau Inside Neurally-Derived Extracellular Vesicles
Dominic Walsh, PhD—Brigham & Women's Hospital and Harvard Medical School
3:40-3:50Q&A
3:50-4:00pmClosing Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation